XML 41 R27.htm IDEA: XBRL DOCUMENT v3.22.2
STOCK-BASED COMPENSATION (Tables)
6 Months Ended
Jun. 30, 2022
STOCK-BASED COMPENSATION [Abstract]  
Stock Option Granted

During the three and six months ended June 30, 2022 and 2021, the Company granted the following stock options (in thousands):


 
 
Three months ended June 30,
   
Six months ended June 30,
 
 
 
2022
   
2021
   
2022
   
2021
 
Stock options granted
   
723
     
3,366
     
1,981
     
3,366
 
Weighted-Average Assumptions Used for Stock Options Granted

The following weighted-average assumptions were used for stock options granted during the three and six months ended June 30, 2022 and 2021:


    Three months ended June 30,  
 
 
2022
   
2021
 
Weighted average risk-free rate
   
2.74%

   
1.06%

Weighted average volatility
   
92.74%

   
134.30%

Dividend yield
   
0%

   
0%

Expected term
 
4.15 years
   
6.08 years
 


   
Six months ended June 30,
 
   
2022
   
2021
 
Weighted average risk-free rate
   
2.42%

   
1.06%

Weighted average volatility
   
92.85%

   
134.30%

Dividend yield
   
0%

   
0%

Expected term
 
4.79 years
   
6.08 years
 
RSU Granted

During the three and six months ended June 30, 2022 and 2021, the Company granted the following restricted stock units (“RSUs”) (in thousands):


 
 
Three months ended June 30,
   
Six months ended June 30,
 
 
 
2022
   
2021
   
2022
   
2021
 
RSUs Granted
   
-
     
105
     
1,101
     
105
 
RSUs Vested and Settled The following table shows the number of RSUs that vested and were settled during the three and six months ended June 30, 2022, as well as the number of shares of common stock withheld to cover the withholding taxes and the net shares issued upon settlement (in thousands):


 
 
Three months ended
   
Six months ended
 
 
 
June 30, 2022
   
June 30, 2022
 
RSUs vested
   
26
     
35
 
Common stock withheld to cover taxes
   
(9
)
   
(9
)
Common stock issued
   
17
     
26
 
Stock-Based Compensation Expense

For the three and six months ended June 30, 2022 and 2021, the Company recognized stock-based compensation expense as follows, which includes the expense related to Dr. Federoff’s modified awards discussed above (in thousands):


 
 
Three months ended June 30,
   
Six months ended June 30,
 
 
 
2022
   
2021
   
2022
   
2021
 
Research and development
 
$
470
   
$
168
   
$
892
   
$
570
 
General and administrative
   
409
     
986
     
1,170
     
1,003
 
Total
 
$
879
   
$
1,154
   
$
2,062
   
$
1,573